Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 5/20 | 0.63 |
| ▸ | AKT1 | P31749 | 5/20 | 0.51 |
| ▸ | ACLY | P53396 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29190458 | 0.84 | NOTUM (0.72) | NOTUMHDAC1HDAC6CNR2 | |
| SCHEMBL15676941 | 0.83 | NOTUM (0.53) | NOTUMAKT1ACLYHDAC1HDAC6 | |
| SCHEMBL30898670 | 0.83 | NOTUM (0.53) | NOTUMAKT1ACLYHDAC1HDAC6 | |
| SCHEMBL30232786 | 0.82 | NOTUM (0.63) | NOTUMAKT1HDAC1HDAC6 | |
| SCHEMBL1572534 | 0.82 | NOTUM (0.63) | NOTUMAKT1HDAC1HDAC6 | |
| SCHEMBL30232632 | 0.81 | NOTUM (0.61) | NOTUMHDAC1HDAC6 | |
| SCHEMBL23671532 | 0.80 | PIK3CA (0.42) | NOTUMAKT1ACLYALDH1A1 | |
| SCHEMBL23671543 | 0.80 | NOTUM (0.40) | NOTUMAKT1ACLY | |
| SCHEMBL22003803 | 0.79 | SLC18A3 (0.50) | NOTUMAKT1ACLYHDAC1HDAC6 | |
| SCHEMBL2801666 | 0.78 | NOTUM (0.58) | NOTUMHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3950682-B1 | PREPARATION METHOD FOR AMIDE COMPOUNDS AND USE THEREOF IN MEDICAL FIELD | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO LTD (CN) | 2026-02-11 | — | — | EP | disclosed |
| US-12473298-B2 | Amide compounds, preparation method therefor, and use thereof in the medical field | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD. (CN) | 2025-11-18 | — | — | US | disclosed |
| CN-113330008-B | Preparation method of amide compound and application of amide compound in medicine field | 上海华汇拓医药科技有限公司 | 2024-05-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473298-B2 | Amide compounds, preparation method therefor, and use thereof in the medical field | EZH2, IKZF2, EZH1 | NOTUM 265/4885AKT1 734/4885ACLY 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.